Know Cancer

forgot password

A Pilot Phase I Dose Finding Safety Study of a Thrombopoietin-receptor Agonist, Eltrombopag, in Patients With Myelodysplastic Syndrome Treated With Azacitidine

Phase 1
18 Years
Not Enrolling
Myelodysplastic Syndrome, Thrombocytopenia

Thank you

Trial Information

A Pilot Phase I Dose Finding Safety Study of a Thrombopoietin-receptor Agonist, Eltrombopag, in Patients With Myelodysplastic Syndrome Treated With Azacitidine

Inclusion Criteria:

1. Adult subjects (18 years of age or older) with advanced MDS or sAML/MDS requiring
treatment with Azacitidine as approved by EMEA:

- MDS classified as Intermediate 2-risk or high risk according to the
international prognostic scoring system (IPSS) or

- Chronic myelomonocytic leukaemia (CMML) with 10-29% bone marrow blasts without
myeloproliferative disease or

- Acute myeloblastic leukaemia (AML) with 20-30% bone marrow blasts with
multilineage dysplasia according to the WHO classification.

2. Platelet counts < 75 x 109 /L at start of Azacitidine treatment.

3. Subjects must have platelet count and platelet transfusion data available over a
period of 4 weeks prior to inclusion.

4. During the 8 weeks prior to inclusion in study, subjects must have a baseline bone
marrow examination including all of the following:

- cytomorphology to confirm bone marrow blasts

- cytogenetics

5. ECOG Status 0-2.

6. Subject is able to understand and comply with protocol requirements and instructions.

7. Subject has signed and dated informed consent.

8. Adequate baseline organ function defined by the criteria below:

- total bilirubin (except for Gilbert's Syndrome)
- ALT and AST
- creatinine
9. Subject is practicing an acceptable method of contraception (documented in
CRF).Female subjects (or female partners of male subjects) must either be of non
childbearing potential (hysterectomy, bilateral oophorectomy, bilateral tubal
ligation or post-menopausal > 1 year), or of childbearing potential and use 1 of the
following highly effective methods of contraception (i.e., Pearl Index < 1.0%) from 2
weeks prior to administration of study medication, throughout the study, and 28 days
after completion or premature discontinuation from the study:

- Complete abstinence from intercourse;

- Intrauterine device (IUD);

- Two forms of barrier contraception (diaphragm plus spermicide, and for males
condom plus spermicide);

- Male partner is sterile prior to entry into the study and is the only partner of
the female;

- Systemic contraceptives (combined or progesterone only).

Exclusion criteria:

1. Subjects with a diagnosis of acute promyelocytic leukemia.

2. Patients with short life expectancy (less than 3 months)

3. Patients with bone marrow fibrosis that does not allow bone marrow aspiration
(so-called "dry tap") or fibrosis grade II or III (grading according to European
consensus on grading bone marrow fibrosis.

4. History of treatment for cancer other than MDS or sAML/MDS with systemic chemotherapy
and/or radiotherapy within the last 2 years.

5. Patients with clinically significant splenomegaly, or > 16 cm spleen in length
measured by ultrasound

6. Patients with known liver cirrhosis

7. Patients with East Asian ancestry such as Chinese, Japanese, Taiwanese or Korean.

8. History of treatment with romiplostim or other TPO-R agonists.

9. subjects with a QTc > 450 msec (QTc > 480 msec for subjects with Bundle Branch

10. Subjects with known thrombophilic risk factors. Exception: Subjects for whom the
potential benefits of participating in the study outweigh the potential risks of
thromboembolic events, as determined by the investigator.

11. Female subjects who are nursing or pregnant (positive serum or urine Beta-human
chorionic gonadotropin [B-hCG] pregnancy test) at screening or pre-dose on Day 1.

12. Current alcohol or drug abuse.

13. Treatment with an investigational drug within 30 days or 5 half-lives (whichever is
longer) preceding the first dose of study medication.

14. Active and uncontrolled infections.

15. Subjects infected with Hepatitis B, C or Human Immunodeficiency Virus (HIV).

Type of Study:


Study Design:

Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Outcome Measure:

Safety and tolerability parameters

Outcome Description:

Including: Non-hematological clinical, laboratory Grade 3/Grade 4 toxicities Change in bone marrow or peripheral blood blast counts from baseline Adverse events and interactions at increasing doses of eltrombopag

Outcome Time Frame:

week 26

Safety Issue:


Principal Investigator

Tobias Svensson, M.D.

Investigator Role:

Study Director

Investigator Affiliation:

Nordic MDS Group


Sweden: Medical Products Agency

Study ID:




Start Date:

October 2011

Completion Date:

May 2013

Related Keywords:

  • Myelodysplastic Syndrome
  • Thrombocytopenia
  • Myelodysplastic syndrome
  • azacitidine
  • Eltrombopag
  • Thrombopoietin-receptor agonist
  • Thrombocytopenia
  • Transfusion dependency
  • Safety study
  • Myelodysplastic Syndromes
  • Preleukemia
  • Thrombocytopenia